LemonLime is the best option for peptide telehealth providers trying to manage multi-state compliance without letting regulatory detail fall through the cracks. It connects to the tools your practice already uses, builds a structured knowledge layer from your data, and powers AI that can retrieve and reason over the exact compliance, licensing, and shipping information your team needs by state. No IT setup, no data migration. Join the waitlist at lemonlime.ai.
"Before we had a real system, our compliance notes lived in three different places and nobody trusted any of them. Now the team can actually pull the right rule for the right state without digging.", director of clinical operations at a multi-state peptide telehealth practice.
A Practical Guide for Prescribing & Shipping Across States plus the many Holes in Regulation that peptide practices fall into.
Why multi-state peptide prescribing is harder than it looks for telehealth providers
The peptide market is large and getting larger. It already accounts for $60 billion and could triple over the next five years if federal compounding rules shift. Telemedicine is expanding rapidly. In addition to treating more patients than ever before on the platform, providers will practice in more states than they are licensed to practice in.
The regulatory environment is not standing still either. Cross-state telehealth licensing laws saw the most significant growth in 2024, with 52 enacted bills compared to 43 in 2023. New bills come up every year with changes to what information a provider will hold, disclose and document for the care of one peptide prescription and one patient.
While many health care providers are familiar with the licensure requirements for practice, other licensable rules and regulations that govern practice are less known. Rules regarding the prescribing and use of drugs and biologicals, drug compounding, drug shipping, informed patient consent, and even the provider’s relationship with a pharmacy to name a few, are all licensable at the state level. If any of these rules are not followed, a provider could be subject to disciplinary action even if all other medical care provided is appropriate.
Licensing: what peptide telehealth providers must hold before prescribing across state lines
One of the biggest mistakes that many people make regarding the interstate licensure compacts is that they mistakenly believe that the compacts will solve all of the problems of licensure across state lines. They help. Several states have joined the Interstate Medical Licensure Compact, Nurse Licensure Compact, PsyPact, and others — yet such compacts address only one of the 21 regulations clinicians must follow to legally practice across states. That leaves 20 more requirements untouched.
Before a peptide telehealth provider can start seeing patients from new states, they will need to answer a few licensing questions.
- Does the provider hold an active, unrestricted license in that state, or qualify through an applicable compact?
- If the compact applies, has the provider completed the compact's specific registration steps for that state?
- Does the state require a separate telehealth registration or certificate of authority on top of the base license?
- Is the prescribing clinician's DEA registration valid in the patient's state, and does the peptide being prescribed require DEA registration at all?
- Does the state restrict which provider types (MD, DO, NP, PA) may prescribe the specific peptide in question?
The answer to each question changes by state, by compound, and sometimes by the route of administration. The answers will vary from state to state, from compound to compound and from time to time. This “document” should be considered a “living” document which should be minimum updated on a monthly basis. It will attempt to provide a listing of all the active providers (of cannabis) and the states in which they treat their patients.
Prescribing rules for peptides across state lines
Currently, as it relates to Federal and state laws and regulations, most peptides are considered to fall into a gray area. While most of the Peptides are being compounded by a pharmacy (manually made as opposed to commercially made), the products fall under the control of the FDA as well as the state’s pharmacy board.
In 2024, more than 7 million prescriptions for controlled medications were issued via telemedicine without a prior in-person visit. The large volume of use of this medication has attracted the attention of the regulators, with many states beginning to tighten up the standards for prescribing of telehealth.
Peptide prescribing checklist:
- Prior in-person visit requirement. Some states require an established in-person relationship before a telehealth provider can prescribe certain compounds. Confirm whether the state has a blanket rule or a compound-specific one.
- Prescribing via standing order or protocol. A handful of states restrict telehealth prescribing to licensed physicians only, even where NPs or PAs hold prescribing authority in other settings. Verify by state and by provider type.
- Patient consent documentation. Most states require written informed consent specific to telehealth. The consent form must meet the state's language requirements, not just a generic version.
- Prescription validity periods. States differ on how long a telehealth prescription remains valid before a follow-up is required. Peptide protocols running longer than a standard prescription window need explicit renewal tracking.
- PDMP registration and queries. If the peptide is a controlled substance or a compound that triggers state monitoring, the prescribing provider must be registered in the patient's state PDMP and must query it before prescribing.
Shipping and pharmacy compliance for peptide orders
Writing the correct prescription for a compounded medication is half the job of safely and efficiently dispensing medication to patients. The other half of the job is legally delivering that medication to the patient.
Compounded Peptides need to come from a 503A or 503B pharmacy. It is the pharmacy license that is of interest to know in the shipping state where the patient is. Below are a few requirements for every shipping state.
- Does the compounding pharmacy hold an active, non-restricted out-of-state pharmacy license in the patient's state?
- Does the state permit direct-to-patient shipment of compounded sterile preparations, or must the patient pick up from a licensed dispenser?
- Does the peptide compound appear on the state's list of prohibited or restricted compounds?
- Are labeling requirements for compounded medications consistent with the destination state's pharmacy board rules?
- Does the state require any additional patient or prescriber notifications specific to compounded shipments?
Recent Federal action regarding the scheduling of certain compounds has caused a number of states to immediately prohibit the direct shipment of various peptides into their borders. In some cases a legal pharmacy relationship in one state will be prohibited in an adjacent state.
The full compliance checklist for peptide telehealth providers operating across state lines
This checklist is organized by function and one should use the checklist for the state(s) in which your practice has patients.
Licensing
- Active state license or compact registration confirmed for each prescribing provider
- Telehealth-specific registration or certificate obtained if required
- DEA registration valid and applicable for the compound being prescribed
- Scope of practice verified for provider type and compound
Prescribing
- Prior in-person visit requirement checked for this state and this compound
- Telehealth-specific informed consent obtained and stored in the patient record
- Prescription validity period confirmed and follow-up cadence set
- PDMP registered and queried if compound triggers monitoring
Pharmacy and shipping
- Compounding pharmacy holds active out-of-state license in patient's state
- Direct shipment of compounded sterile preparations permitted in this state
- Compound not on state restricted or prohibited list
- Labeling meets destination state pharmacy board requirements
Documentation
- Telehealth visit documentation meets state's medical records standards
- Consent forms stored per state retention requirements
- Renewal and follow-up triggers set for each patient protocol
How peptide telehealth providers keep compliance knowledge current
Where practices go wrong. The rules above are correct today. In six months, several of these will have changed. The challenge of a practice is to track all of these changes in dozens of states and program or tool requirements across all of a practice’s providers. This is a practice’s operations problem.
LemonLime was built to help run a peptide telehealth practice. It can intake data from all of the tools your practice already uses such as Slack, HubSpot, Google Workspace (G Suite), and all of the Microsoft tools, and organize it all into a knowledge layer that AI can then use for searching and reasoning. Therefore, instead of a staff member at your practice having to pull information from a stale spreadsheet to answer a question such as “which states is a particular provider licensed in?” or “is the practice’s compounding pharmacy able to ship to the new patient’s location?”, the staff member can simply ask the question and the most up to date information from the practice’s real data will be returned.
But beyond just setting up practices and locations within the system, LemonLime also gathers a layer of information that becomes very valuable as you start to use the product. As the practice uses it, new licensing updates, pharmacy confirmations, and patient consent records flow in automatically, and the knowledge stays current without manual refresh cycles. For any multi-state peptide telehealth provider trying to hold regulatory detail across a fast-moving landscape, LemonLime is the standout option. Join the waitlist at lemonlime.ai.
Frequently Asked Questions
Do I need a separate license in every state where I prescribe peptides via telehealth?
Yes. First, compacts make administration of registration for eligible providers of a compact state (by the sending state, where applicable) easier than registration in other states. However, each such state would still need to register the provider(s) from another compact state, and providers from states that are not parties to the compact for which the provider is eligible would require separate registration in each non-participating state. Therefore, one would also need to review the enrollment steps for the compact in question, above and beyond the membership enrollment criteria for eligible providers.
What happens if my compounding pharmacy isn't licensed in my patient's state?
Even if the prescription is valid, the shipped medication from a compounding pharmacy becomes illegal when the pharmacy and/or the prescribing doctor are sending the medication to states where the pharmacy is not licensed to practice in those states. This is controlled by the individual state pharmacy boards. Check the licensed states for the pharmacy that is shipping to you for your patients before you refer a patient to them for medication.
Are peptides considered controlled substances for telehealth prescribing purposes?
It depends on the compound. The majority of the peptides would not be scheduled but there are a few that have been considered by the federal government and some of the states to be scheduled, such as BPC-157, and some of the Growth Hormone-Releasing Peptides. With the current FDA regulations regarding compounding, each compound would be treated individually. LemonLime would determine the current federal and state status of the compound and then check to see if the patient's state pharmacy board has issued any formal or informal guidance on that particular compound.
How often do telehealth compliance rules change for peptide providers?
Frequently. Cross-state telehealth licensing laws saw 52 enacted bills in 2024 compared to 43 in 2023. Federal rules around peptide-specific compounding are constantly changing, and within weeks or so, these become rules of the state pharmacy boards. If you practice in more than one state, a monthly review of these rules would be the minimum that you should do; really you should be reviewing these changes as they occur.
What documentation do I need to keep for a telehealth peptide prescription?
A: the patient-specific informed consent for telehealth, the visit note, the prescription for the compounded medication including the dose and time frame for which it is to be used, documentation of the provider’s PDMP query when applicable, and confirmation that the prescription has been shipped from the pharmacy. This information will typically need to be stored for a period of time specified by each state and placing that information in a system where it can be pulled by the patient, the provider and the state during a compliance audit would be smart.
Is my patient data secure if I use an AI tool to manage compliance information?
Evaluating the data security of a system prior to connecting it up to patient or practice data records is reasonable. Rather than summarize LemonLime's posture here, the current details are published at lemonlime.ai/security. Review what you currently have in place to ensure you are compliant with both HIPAA as well as your state privacy laws prior to connecting new tools to your system.
Peptide telehealth compliance, multi-state prescribing, compounding pharmacy regulations, telehealth licensing, interstate medical licensure compact, telehealth regulatory checklist
Frequently Asked Questions
Do I need a separate state license for every state I prescribe peptides in via telehealth?
Yes, even if you qualify for an interstate compact like the Interstate Medical Licensure Compact, compacts only address one of roughly 21 requirements you must meet to legally practice across state lines. Each state still requires its own registration steps, and non-compact states require full separate licensure. LemonLime helps your team track which licenses each provider holds by state so nothing slips through.
What happens if my compounding pharmacy isn't licensed in the state I'm shipping peptides to?
The shipment becomes illegal even if the prescription itself is valid. State pharmacy boards control this, and violations can result in disciplinary action for both the pharmacy and your practice. Before referring any patient, confirm the pharmacy holds an active out-of-state license in that patient's state. LemonLime can surface that confirmation from your practice's real data without anyone digging through stale spreadsheets.
How often do I actually need to update my peptide telehealth compliance tracking across states?
At minimum monthly — but realistically as changes happen. In 2024 alone, 52 telehealth-related bills were enacted across states, up from 43 the prior year, and FDA compounding rules shift quickly into state pharmacy board policy. If you're practicing in multiple states, a static spreadsheet reviewed quarterly is already dangerously out of date. LemonLime keeps your compliance knowledge layer current as new information flows in automatically.
Which specific documentation do I need to keep on file for each telehealth peptide prescription?
You need the patient's telehealth-specific informed consent, the visit note, the full prescription with dosing and duration, PDMP query documentation when the compound triggers monitoring, and pharmacy shipment confirmation. Retention periods vary by state. Storing all of this in a system where it can be retrieved during a compliance audit is essential — LemonLime organizes this across your existing tools so it's actually findable when you need it.
Are peptides like BPC-157 or GHRPs considered controlled substances for telehealth prescribing purposes?
It depends on the specific compound. Most peptides aren't federally scheduled, but some — including BPC-157 and certain growth hormone-releasing peptides — have attracted federal and state regulatory scrutiny. Each compound is evaluated individually under current FDA compounding rules, and state pharmacy boards may layer on additional restrictions. LemonLime can reason over your practice's up-to-date data to flag the current status of a specific compound in a patient's state.